Clinical trial
An Induction Study of Mirikizumab in Participants With Moderately to Severely…
NCT03518086 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT03518086 |
|---|---|
| Title | An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) |
| Official title | A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Mirikizumab, Placebo |
| Enrollment | 1,281 |
| Start date | Jun 18, 2018 |
| Primary completion | Jan 21, 2021 |
| Completion | May 15, 2024 |
| First posted | May 8, 2018 |
| Last update posted | May 31, 2025 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, China, Croatia, Czechia, Denmark, France, Germany, Hungary and 23 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: